Aram Mkhitarian, DO
Internal Medicine · Newbury Park, CANPI 1952565301
Payments from drug & device makers
Across 20 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$251
- Kowa Pharmaceuticals America, Inc.$129
- Novartis$24
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$23
- Tolmar, Inc.$17
What the payments were for
- Food & beverage$443100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 10 | $251 |
| Kowa Pharmaceuticals America, Inc. | 7 | $129 |
| Novartis | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Tolmar, Inc. | 1 | $17 |
How this compares
$443 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 81 | $143,384 |
| OzempicSemaglutide | 48 | $46,497 |
| EliquisApixaban | 49 | $36,237 |
| LinzessLinaclotide | 45 | $25,582 |
| MounjaroTirzepatide | 25 | $25,300 |
| AvodartDutasteride | 12 | $15,374 |
| Repatha SureclickEvolocumab | 22 | $12,994 |
| XareltoRivaroxaban | 18 | $10,633 |
| Fenofibrate | 15 | $9,660 |
| MyrbetriqMirabegron | 14 | $8,749 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $8,634 |
| Metformin Er GastricMetformin Hcl | 15 | $6,718 |
| MeloxicamMeloxicam, Submicronized | 11 | $6,604 |
| Icosapent Ethyl | 25 | $5,711 |
| Oxiconazole Nitrate | 13 | $5,604 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Newbury Park
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.